PRODUCT TYPES – Page 10

Vector potency drift during stability testing: regulatory risk assessment and CAPA

Identifying early signals of vector potency drift is crucial for timely intervention and effective investigations. Common symptoms may include:Click to read the full article.

API starting material traceability gap during FDA inspection readiness: regulatory impact assessment and change control remediation plan

Evaluating and Addressing API Starting Material Traceability Gaps for FDA Inspection Readiness In the highly regulated pharmaceutical manufacturing environment, the ability to demonstrate robust traceability for active pharmaceutical ingredients (APIs)…

Cryopreservation failure during tech transfer: regulatory risk assessment and CAPA

Identifying the symptoms and signals of a cryopreservation failure is crucial for immediate containment and subsequent investigation. These symptoms can vary but generally manifest in the following ways:Click to read…

Finished product microbial limits failure after scale-up to commercial equipment: how to defend specification setting and outlier handling during inspection

Identifying the symptoms or signals of a microbial limits failure is critical for initiating an effective investigation. These symptoms can manifest in various forms:Click to read the full article.

Aseptic manipulation deviation during ATMP manufacturing: regulatory risk assessment and CAPA

Recognizing the initial signals of a deviation is crucial. Symptoms may manifest in various ways, including:Click to read the full article.

Finished product impurity increase on stability after process parameter adjustment: risk assessment for patient impact and field alert / recall triggers

Detecting changes in product quality often begins with visual or analytical signals. In this investigation scenario, several key symptoms may indicate an issue with finished product stability:Click to read the…

Aseptic manipulation deviation during tech transfer: regulatory risk assessment and CAPA

Recognizing symptoms of aseptic manipulation deviations is essential for timely intervention. Common indicators include:Click to read the full article.

Finished product extractables & leachables signal during deviation triage meeting: data integrity review steps for LIMS/EMR/ES and chromatography systems

Recognizing the symptoms that indicate potential issues with extractables and leachables is the first step in a successful investigation. Symptoms may manifest as deviations noted during routine quality control (QC)…

Chain of identity breach during scale-up: inspection-ready investigation package

Identifying symptoms of a chain of identity breach is crucial for early intervention. Common signals include:Click to read the full article.

Finished product transport excursion stability impact during routine batch release: CAPA plan that inspectors accept (with effectiveness checks and due dates)

The first step in addressing transport excursion stability impacts is recognizing the symptoms or signals that indicate a potential issue. Common signals may include:Click to read the full article.

Aseptic manipulation deviation during ATMP manufacturing: patient safety impact and disposition

Recognizing the initial signs of a potential aseptic manipulation deviation is crucial for timely intervention and investigation. Symptoms may manifest in multiple forms and can include:Click to read the full…

Finished product serialization data mismatch during recall risk assessment: CAPA plan that inspectors accept (with effectiveness checks and due dates)

The detection of a finished product serialization data mismatch typically manifests itself through various symptoms, which can occur during routine quality checks, audits, or when performing recall risk assessments. Some…